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Background: Adverse drug reactions (ADRs) are a leading cause of morbidity in developed countries and represent
a substantial burden on health-care resources. Many countries spent 15% to 20% of their hospital budgets to treat
drug complications. However, few studies have measured the pharmacoeconomic effects of ADRs on hospitalized
patients in China. The study estimates the costs of ADRs as identified from the spontaneous voluntary reports
completed from healthcare professionals. To do so, we calculate these costs, determine the sum of Medicare
payments and their proportion of total healthcare spending, and evaluate the incidence of ADRs, characteristics of
hospitalized ADR patients, and outcomes of ADRs in China.
Methods: This retrospective survey studied patients who experienced ADRs during their hospitalization at a
Chinese tertiary-care teaching hospital. The patients were divided into group A and group B according to general
ADRs and serious ADRs in Provisions for Adverse Drug Reaction Monitoring and Reporting. The direct costs included
treatment fees, inspection fees, laboratory fees, materials fees, bed charges, drug charges, nursing care, meals, and
other expenses and the sunk-cost losses were calculated according to the hospital information system (HIS). Indirect
costs of ADR treatment were calculated according to the human capital approach. The epidemiological
characteristics of ADRs were evaluated.
Results: 2739 were diagnosed with ADR during the study period, which translates to an ADR rate of 0.81%. The total
socioeconomic loss from 2739 cases of ADR was estimated at ¥817401.69, consisting of direct costs of ¥603252.81 and
indirect costs of ¥214148.88. On average, the costs per patient amounted to ¥196.10 in group A, ¥7032.29 in group B.
The sum of medicare payment and proportion were ¥219061.13 (65.23%) and ¥105422.02 (39.42%) in group A and B.
The ADR incidence in old-age patients was significantly higher than in other age groups (P < 0.0001). The most
common drug class associated with ADRs represented antibiotics (957 patients, 34.94%).
Conclusions: The costs of especially severe ADRs could not be ignored, and in this hospital 0.13% of patients were
diagnosed with ADRs associated with relatively higher direct costs than who suffered from mild ADRs, largely due to
extended hospitalization.
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It is estimated that adverse drug reactions (ADRs) ranked
fourth to sixth on the factors that caused death in the
United States; every year, hundreds of thousands of deaths
directly resulted from ADR [1]. In many countries, ADRs
accounted for more than 10% of the total number of
hospitalization cases [2]. The treatment of diseases caused
by ADRs requires a huge amount of financial resources,
and many countries spend 15% to 20% of hospital budgets
to treat drug complications [3,4]. Johnson and Bootman
[5] show that the United States spends about $30.1 to
$136.8 billion each year to deal with drug-related prob-
lems (DRPs). All the uncertainty associated with their esti-
mations was evaluated by many scholars. This estimate
was updated by Ernst and Grizzle to $177.4 billion for the
year 2000 [6]. Of this amount, health-care-related drug
costs accounted for the biggest part. Monitoring and ana-
lyzing ADR treatment costs has become a key research
topic in Europe and the United States in recent years [7,8].
Hoonhout [9] and colleagues estimate that direct medical
costs in Dutch hospitals amounted to euro 355 million per
annum for all AEs and euro 161 million for preventable
AEs in 2004.
China witnessed the beginnings of an ADR reporting and
monitoring system in 1999. In 2011, this was upgraded to a
comprehensive spontaneous reporting system (SRS) [10].
All units and individuals engaged in drug production, man-
agement, and usage in the country must report all suspi-
cious ADRs and adverse drug events (ADEs) through the
SRS. Since October 2003, hospitals in China have had a
spontaneous ADR reporting unit, coordinated by their
pharmacy practice departments. ADR reporting units of
hospitals are peripheral centers under the National Phar-
macovigilance Program. Through the SRS and the National
Pharmacovigilance Program, the State Food and Drug Ad-
ministration regularly publishes information on adverse
drug reaction and revocation of drug approvals [11,12]. We
can now provide a data infrastructure for ADR research
with the accumulated ADR statistics. However, few phar-
macoeconomics research studies on ADRs have examined
the incidence of ADRs in China or the epidemiological
characteristics of the disease. The objectives of this study
are to (1) calculate the costs associated with different de-
grees of ADRs and determine total Medicare payments on
ADRs as well as their proportion of total healthcare spend-
ing and (2) evaluate the incidence of ADRs, characteristics
of hospitalized ADR patients, and outcomes of ADRs.
Methods
Setting
In this retrospective, descriptive research based on data
derived from a spontaneous reporting system, we collected
data of all cases of ADR that occurred during inpatient
procedures at the First Affiliated Hospital of BengbuMedical College from January 1, 2008 to December 31,
2012. All ADR cases reported to the database of the Center
of Adverse Drug Reaction Monitoring through the SRS
were retrospectively analyzed. Cases of ADR induced by
drug-drug interactions were also included in the study. The
following data were obtained from the clinical records of
patients who suffered from ADR: (1) demographic informa-
tion of patients, such as sex and age, medications taken
prior to admission, history of drug allergy; (2) the sequence
of ADR events and incidental information, such as time of
occurrence, time of adoption of intervention measures to
ADR , termination time of the ADR, the symptoms, signs,
and related diagnostic findings when the ADR first oc-
curred, therapy duration, and drug classes involved; (3)
variation in symptoms, signs, and related diagnostic find-
ings, the results of intervention measures, etc. The hospital
is a large teaching tertiary hospital with 1936 beds. All the
ADRs were re-evaluated according to the Provisions for Ad-
verse Drug Reaction Monitoring and Reporting [13] issued
in 2011, as well as the Naranjo scoring algorithm [14]. The
drugs involved in the ADRs were codified into various drug
classes according to their anatomical therapeutic chem-
ical (ATC) classifications based on the World Health
Organization (WHO) ATC Index of 2005 [15]. To ad-
dress the issue of redundant and variable drug nomen-
clature, ADR names were coded by using the preferred
terms in the WHO Adverse Reaction Terminology
(WHO-ART) guidelines, which have been used for
more than 30 years for the rational coding of adverse re-
action terms [16]. The conditions were evaluated by a
panel of three experts: a pharmacist, a physician, and a
clinical pharmacologist. In case of any disagreement be-
tween their scores, we reached a consensus of scores by
discussion. They reviewed all the available information
in the reports; when necessary, the reporter of ADRs
was contacted for follow-up information. Only ‘possible’,
‘probable’, and ‘definite’ ADRs that scored more than 1
were taken into consideration; the causality of these ADRs
was also classified according to the methodology of
Naranjo et al. [14]. For cases with sequelae and deaths,
only costs incurred during hospitalization were estimated,
because the treatment cannot be tracked after the patients
are discharged from hospital and hidden costs are difficult
to calculate.
Grouping of cases
All the ADR cases were divided into two groups according
to serious ADRs and general ADRs in Provisions for Ad-
verse Drug Reaction Monitoring and Reporting [13]. Cases
with general ADRs that could be rehabilitated without any
treatment, other than stopping the administration of drugs
or Cases that did not require hospitalization, or prolong
hospitalization, but could be rehabilitated with other drugs
or therapeutic, belonged to group A. Cases with serious
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Drug Reaction Monitoring and Reporting belonged to
group B. An ADR condition belonged to group B if it (1)
caused death; (2) posed a threat to life; (3) led to signifi-
cant or permanent human disability or organ damage; (4)
led to brief or prolonged hospitalization; or (5) led to other
important medical events. Mild reactions could auto-heal
after discontinuation; moderate reactions do not result in
prolonged hospitalization but could be cured by other
drugs/treatment; severe reactions prolong hospitalization
or other important medical events.
Measurement of direct costs
Direct costs refer to direct medical costs, which include
treatment fees, inspection fees, laboratory fees, materials
fees, bed charges, drug charges, nursing care, meals, and
other expenses from the beginning of the ADR to the ter-
mination of treatment. Calculation of direct costs may be
based on the electronic medical data accumulated in the
hospital information system (HIS). The costs of group A
were calculated as the sum of the sunk-cost losses and the
direct costs. If an expense incurred cannot be recovered, a
rational person would ignore it. This type of expenditure
is called a sunk cost. From a rational perspective, a sunk
cost that cannot be recovered should not affect the con-
sumer’s purchase decision or attitude. However, previous
studies have shown that in the consumer decision-making
process, the sunk cost effect cannot be ignored [17,18].
Sunk costs in the research mainly refer to the remaining
drug and other costs (tutelage costs, etc.) due to the with-
drawal of treatment and, therefore, the inability to reuse
the ADR drug prescribed for the treatment of the original
illness [19,20]. Sunk cost calculation was based on wasted
drug and treatment costs accumulated in the HIS. The
direct costs included treatment fees, inspection fees, la-
boratory fees, materials fees, bed charges, drug charges,
nursing care, meals, and other expenses. Transportation
costs, nutrition costs of the patients, and non-project de-
partment costs (services provided by indirect departments
for example the administrative and logistical departments)
were not included. The actual loss to the patient was esti-
mated considering health-care insurance coverage avail-
able. As electronic information in the HIS record had
been lost or was incomplete, cost statistics were based on
average direct or sunk costs calculated from available pa-
tient data. However, this research encountered very few
cases of this sort.
Measurement of indirect costs
Indirect costs of ADR treatment were calculated according
to the human capital approach (based on the 2011 GDP
per capita of 19907.91 yuan for Bengbu district). Only loss
of working time was estimated considering the practicabil-
ity of the study. The calculation formula was as follows:lost income due to hospitalization = number of days in
hospital × per capita GDP/365 for Bengbu district; lost in-
come from accompanying hospitalized patient = number
of days in attendance (e.g., number of days a child was hos-
pitalized) × per capita GDP/365 of the concerned city (only
one person was reckoned for pediatric hospitalization
cases); lost income for an outpatient = number of out-
patient visits due to ADR × per capita GDP/730 of the con-
cerned city (one outpatient visit regarded as 0.5 days lost).
The indirect costs of groups A and B were calculated ac-
cording to the formula for the cost of inpatient care. Only
when some ADR cases in group A self-heal after stopping
drug treatment can the indirect costs of group A (about
one outpatient per case) be calculated from lost outpatient
income based on actual outpatient visits. The overall socio-
economic loss includes direct, indirect, and hidden costs.
Direct and indirect costs were estimated as described in this
paper. However, hidden costs, representing the pain, sad-
ness, and depression of patients, were not considered in the
present study because they were too difficult to measure.
Data sources
All ADR cases were identified from the Chinese Adverse
Drug Reaction Monitoring and Reporting database (www.
adr.gov.cn). To calculate the incidence of adverse reactions,
we investigated the total number of hospitalized patients
during the study period through the HIS.
Statistics
Numerical data were presented as number of observations
and constituent ratios; chi-square and Fisher’s exact prob-
ability were used in univariate hypothesis testing. Descrip-
tive analysis was conducted for quantitative variables. Mean
values and X2 test statistics were used to compare the dis-
tributions of categorical variables. Data are presented as
mean (SD), and categorical variables are expressed as per-
centages of the total number of ADRs. P < 0.05 was consid-
ered statistically significant. Excel was used to create the
ADR database, and the Stata11.0 software was adopted to
analyze the data.
Ethics
This study was approved by the Center of Adverse Drug
Reaction monitoring, Bengbu Food & Drug Administra-
tion in China. The Research was in compliance with the
Helsinki Declaration and was approved by the Ethics
Committee of The First Affiliated Hospital of Bengbu
Medical College.
Results
Pharmacoeconomic consequences of measurement
of ADRs
During the study period, 2973 cases of adverse drug re-
actions/inpatient events were monitored and reported by
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scored below 1 and those whose electronic information in
the HIS record had been lost or was incomplete (234
cases) were excluded. Thus, 2739 cases of ADR were in-
cluded in the study. No deaths occurred during the study
period. In the same period, inpatients in the hospital num-
bered 337,175, and all of them received drug treatment, so
that the ADR rate was 0.85%. Patient ages ranged from
1 day to 99 years with an average of 48.51 ± 19.84 years
(SD); 47.72% of all patients were male. The demographic
characteristics of the patients in groups A, and B are
shown in Table 1.
The total socioeconomic loss from the 2739 cases of
ADR was estimated at ¥817401.69, consisting of direct
costs of ¥603252.81 and indirect costs of ¥214148.88 for
the two groups. Medical insurance payments toward
direct costs amounted to ¥324483.15, and the personal
burden was ¥278778.49 (Table 2). As shown in Table 2,
the total costs for groups A and B were estimated to
be ¥529077.80 and ¥288,323.89, respectively. The direct
cost of group A was ¥335820.06 (63.47% of the total
cost) and the drug cost was ¥178656.19 (33.77%). The
direct cost of group B was ¥267432.75 (92.75% of the
total cost) and the drug cost was ¥183886.91 (63.78%; see
Table 2). The average cost per patient was ¥298.43. with the
average direct costs per patient ¥124.47 and ¥6522.75 and
the average total costs per patient ¥196.10 and ¥7032.29 in
groups A and B, respectively. Finally, the ratios of ADR in-
surance reimbursements to total losses were 65.23% and
39.42% for groups A and B, respectively.
Evaluation of adverse drug reactions
The relationship between adverse drug reaction rates
and patient gender is shown in Table 3. The table showsTable 1 The demographic characteristics of the patients
in the three groups A and B
Group Age group (year)
0-15 16-30 31-45 46-60 61-75 >75 Total
Group A 174 301 667 808 514 234 2698
Male 118 152 237 332 291 153 1283
Female 56 149 430 476 223 81 1415
Group B 2 3 5 8 6 17 41
Male 1 2 1 5 1 14 24
Female 1 1 4 3 5 3 17
Total (%) 176 304 672 816 520 251 2739
(6.43) (11.10) (24.53) (29.79) (18.99) (9.16) (100.00)
Male (%) 119 154 238 337 292 167 1307
(4.35) (5.62) (8.69) (12.30) (10.66) (6.10) (47.72)
Female (%) 57 150 434 479 228 84 1432
(2.08) ((5.48) (15.84) (17.49) (8.33) (3.06) (52.28)that the adverse reaction incidence in female patients is
significantly higher than in male patients (P < 0.05).
There were significant differences in ADR incidence
between different age groups of patients. ADR incidence
per thousand patients increased from 4.48 (0–15 age
group) to 23.73 (61–75 age group), and was statistically
analyzed. The display group (61–75 years) showed sig-
nificantly higher incidence than other age groups (χ2 =
12000, df = 5, P < 0.0001). Table 4 shows that the ADR
incidence in old-age patients was significantly higher
than in other age groups (P < 0.0001).
Antibiotics were the most frequent cause of ADRs,
with 957 patients (34.94%) experiencing an ADR asso-
ciated with this drug class, followed by digestive sys-
tem drugs with 463 patients (16.90%) and traditional
Chinese medicines (TCM) with 427 patients (15.59%).
The top ten drugs that caused adverse reactions are
listed in Table 5 according to WHO Adverse Reaction
Terminology (WHO-ATC) drug coding [15,16]. Levo-
floxacin was the most frequently reported individual
drug (192 patients, 7.01%). Table 4 shows 956 cases of
antibiotic-related ADRs, accounting for 34.90% of the
total number of ADRs. According to the statistical ana-
lysis results, the display group (61–75 years) showed
significantly higher incidence than other age groups
(P < 0.0001).
ADR names are coded with the preferred WHO-ART
terms, which have been developed over more than
30 years to serve as a basis for rational coding of adverse
reaction terms [14]. The following are some important
ADRs with their incidence: skin and appendages disor-
ders, 868 cases (31.69%); body as a whole—general dis-
orders, 837 cases (30.56%); gastro-intestinal system
disorders, 485 cases (17.71%); respiratory system disor-
ders, 145 cases (5.29%); central and peripheral nervous
system disorders, 127 patients (4.64%); heart rate and
rhythm disorders, 103 cases (3.76%); vascular (extracar-
diac) disorders, 102 cases (3.72%); application site disor-
ders, 23 cases (0.84%); hearing and vestibular disorders,
14 cases (5.11%); general cardiovascular disorders, 11
cases (0.40%); musculo-skeletal system disorders, 11
cases (0.40%); urinary system disorders, 5 cases (1.83%);
liver and biliary system disorders, 5 cases (1.83%); and
white cell and red disorders, 3 cases (1.10%).
Mild and moderate reactions accounted for 59.47%
and 39.03%, respectively, of the reported cases, and only
1.5% of the reactions were deemed to be severe, as
shown in Table 1. Two cases of anaphylactic shock
caused extensions of hospitalization by 32 days and
30 days; the shortest case of hospital stay was one day
extended. No deaths occurred, and all patients were
cured. Patients cannot be tracked after discharge from
hospital because the HIS records only information dur-
ing hospitalization.
Table 2 Sum of the cost estimates for ADR cases over 5 years of the two groups
Group Direct cost over 5 years (¥) Sum of indirect costs
over 5 years
Sum of Medicare payments








Total costs, direct costs,
and indirect costs from
the 2739 cases
Sum of drug charges Sum of costs of treatment
and inspection
(¥) (¥) (¥) (¥)
Group A 178656.19 157172.62 193235.84 219061.13 (65.23 %) 335820.06, 124.47 529077.80, 196.10 817401.69, 603252.81, 214148.88






















Table 3 Relationship between gender and adverse
reaction of patient
Sex ADR related Not ADR related Total
Male
No. 1307 167109 168416
Rate (per 1000 patients) 7.76 992.24
Female
No. 1432 167327 168759
Rate (per 1000 patients) 8.49 991.51
Total 2739 334436 337175
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The incidence of adverse drug reactions among hospital-
ized patients during the 5-year period of this study was
0.81%, which was relatively low compared with other
studies [21-23]. First, this retrospective study was based
on a spontaneous reporting and monitoring system,
where underreporting by healthcare workers is a possi-
bility. Although spontaneous reporting is the most
widely used method for routine monitoring of ADRs
[24], it cannot guarantee that a particular adverse event
is a true ADR. Second, it is possible that hospitalized pa-
tients affected by ADR were not included in the study.
Third, the ADR definition in China could be somewhat
different from the definition in other samples studied
[25,26]. The Chinese definition did not include harmful
reactions from normal doses of eligible drugs adminis-
tered for medication. Thus, this definition excludes ad-
verse events due to drug quality, administration with no
indications, and off-label use.
This study showed that the incidence of adverse reac-
tions of female patients was significantly higher than that
of male patients, which was inconsistent with the adverse
reactions study carried out by Agnes Chan in Taiwan [27].
Zhang et al. [28] retrospectively analyze 1001 cases of
ADRs/events induced by traditional Chinese medicine in-
jections and find that the incidence rate in female patients
was higher than that in male patients. In the retrospective
study conducted by Jiang and Kuang [29], the incidence ofTable 4 Correlation of adverse drug reaction (ADR)-related ho
Variable
0-15 16-30
No. of patients (ADR-related hospitalization 176 304
Rate (per 1000 patients) 4.48 4.22
No. of patients (ADR induced by antibiotics) 92 125
Rate (per 1000 patients) 2.34 1.74
No. of patients (non-ADR-related hospitalization) 39067 71690
Rate (per 1000 patients) 995.52 995.78
Total no. of patients 39243 71994severe ADRs was also higher in women than it was in
men. This result may be because TCM injections, used in
many hospitals in China, are more commonly adminis-
tered to women than men [30]. The other reason may be
related to the different sensitivity levels and metabolic pro-
cesses in men and women. Our results are consistent with
Lee’s research finding that adverse reactions are signifi-
cantly higher in patients more than 61 years than in other
age groups [31]. Similar to other researchers in China
[32,33], our study showed that the most common drugs
involved were antimicrobial drugs. However, Jimmy Jose
et al. show that the most common ADRs in 2006 were an-
tineoplastic agents, antiepileptics and antibiotics ranked
only third [25]. In China, more than 60% of inpatients in
hospitals receive antibiotics. This may be due to the wide-
spread clinical use of antimicrobial drugs.
However, developing countries have witnessed a grow-
ing number of ADR studies, following the damaging ef-
fects of the disease on the socioeconomic progress of
those countries. A prospective analysis of 18,820 hospital-
ized patients was carried out in the UK [34]. The result
showed that 1225 hospital admissions related to an ADR,
showing a prevalence rate of 6.5%, with ADR directly lead-
ing to admission in 80% of the cases. The median bed stay
was 8 days, accounting for 4% of the hospital bed capacity.
The projected annual cost of such admissions to the NHS
is￡466 million (€706 million, $847 million). The results of
a prospective study in France showed that hospitalization
costs per ADR patient were about € 11,357.00 [35]. This
study found that the total socioeconomic loss from the 2739
cases of ADR was ¥817401.69 and that the cost per ADR
patient was approximately ¥298.43. This cost is far below
the level of developed countries, which may reflect the lower
medical care and drugs charges in China. For these calcula-
tions, the RMB exchange rate against the US dollar is ap-
proximately 6.061, while the euro exchange rate is
approximately 8.197 [36]. The indirect costs were far less
than the direct costs because chaperone charges and intan-
gible losses were not included in the data. Therefore, the true
value might be far greater than the calculated value in the
present study.spitalizations in China by age group
Age group (years)
31-45 46-60 61-75 >75 Total
672 816 520 251 2739
6.18 11.81 23.73 22.35 8.50
262 248 152 77 956
2.41 3.59 6.94 6.86 2.97
108031 68303 21396 10979 319466
993.82 988.19 976.27 977.65 991.50
108703 69119 21916 11230 322205
Table 5 Top twenty pharmaceuticals that caused ADRs
Generic names ATC code No. Percent (%) Ranking
Levofloxacin J01MA01 192 7.01% 1
Aminomethylbenzoic acid B02AA01 176 6.43% 2
Vitamin K1 B02BA01 89 3.25% 3
Cefathiamidine J01DB01 52 1.90% 4
Mezlocillin J01CE01 48 1.75% 5
Cefoperazone J01DD01 47 1.72% 6
Ciprofloxacin J01MA01 45 1.64% 7
Shenmai injection TCM 42 1.53% 8
Compound amino acid B05B002 40 1.46% 9
Iopromide V08AB02 40 1.46% 9
Sodium Aescinate for injection TCM 36 1.31% 10
Diammonium glycyrrhizinate A05BA08 33 1.20% 11
Cefoperazone sodium and sulbactam sodium for injection J01DD12 33 1.20% 11
Pefloxacin J01MA03 33 1.20% 11
Shengmai injection TCM 31 1.13% 12
Shuganning injection TCM 31 1.13% 12
Tanreqing injection TCM 31 1.13% 12
Cefoxitin J01DC01 31 1.13% 12
Ornithine aspartate A05BA 30 1.10% 13
Shuanghuanglian for injection TCM 28 1.02% 14
Tiopronin A05BA 27 0.99% 15
Matrine A05BA 27 0.99% 15
Cefotiam J01DC07 27 0.99% 15
Ceftazidime J01DD02 27 0.99% 15
Ceftizoxime J01DD07 25 0.91% 16
Cefotiam J01DC07 25 0.91% 16
Enoxacin gluconate J01MA04 25 0.91% 16
Piperacillin sodium and sulbactam sodium/three triazole J01RA01 24 0.88% 17
Fosfomycin J01XX01 24 0.88% 17
Azithromycin J01FA10 23 0.84% 18
Potassium aspartate and magnesium A12BA 23 0.84% 18
Vitamin B6 A11DB 23 0.84% 18
Aztreonam for injection J01DF01 22 0.80% 19
Yadanzi youru zhusheye TCM 20 0.73% 20
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ADR case was 32 days, the shortest period was 2 days, and
the average was 10.8 days. The highest payment was
¥39,873.78, and the lowest was ¥251.13. Although severe
cases were comparatively few, direct costs accounted for
53.14% of the total loss from direct costs. This should be a
focus area for future research. The costs of the two groups
were significantly different, indicating that drug administra-
tion and treatment should be withdrawn promptly after an
ADR occurrence, because most ADRs can be cured by
withdrawal of the suspected drug [37]. To reduce andcontrol serious ADR incidence, we require detailed know-
ledge of the patient’s history regarding food and drug al-
lergy, smoking and drinking, and disease and medication.
In addition, we also need to strengthen drug monitoring,
especially for patients with allergic conditions. This would
greatly reduce the associated costs, and the economic bur-
den on the individual patient, the health-care sector, and
medical institutions. At the same time, we can avoid or
control ADR costs by identifying which of the ADR-related
costs are relatively greater. This would be the topic of a fu-
ture research. There is also a great cost difference between
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should promptly occur after withdrawal and treatment.
Moreover, the reduction and control of the high ADR rate
can greatly reduce costs, both for the patient and for the
health department, thus mitigating the economic burden of
medical institutions. Therefore, how to optimize ADR social
costs is the most important issue.
As shown in Table 2, the proportion of Medicare pay-
ments (in China, people who pay medical insurance on
time are covered by Medicare) increased with the reduction
of medicine costs as a proportion of direct costs. This
shows that drugs used for the treatment of ADRs were
largely outside the scope of Medicare, which caused more
ADRs. The higher the proportion of drug costs, the heavier
the personal burden. Because inspection costs increased in
groups B, and the proportion of drug costs decreased, the
proportion of Medicare payments increased. However,
since drug choice policies and number of patients covered
by Medicare differ across hospitals, the actual proportions
are not consistent with those in this study. According to
the current ADR definitions and relief systems in our coun-
try, personal injury and economic loss caused by ADR
would have to be borne by patients in most cases, though
they could get a certain amount of health insurance com-
pensation. However, because health insurance coverage is
limited at present, the number of insured and amount of
compensation are inadequate.
With price reforms in the current health system under
way, the overall direct economic ADR losses of our hos-
pitals will decrease by 10.54%. Therefore, drug price re-
duction would not only alleviate the problem of the high
medical treatment costs but also help reduce the direct
economic losses caused by ADRs.
The ADR evaluation of this study were similar to those
reported by most domestic studies. However, the study fo-
cused on a single district. Cost estimates of multi-center
studies would greatly enhance credibility. We hope the
ADR monitoring departments of hospitals would initiate
efforts to provide an economic basis for the establishment
of effective ADR relief measures in China.
Conclusions
The costs of especially severe cases of ADR cannot be ig-
nored. In the First Affiliated Hospital of Bengbu Medical
College, 0.13% of patients were identified as suffering from
ADRs associated with higher direct costs largely due to ex-
tended hospitalization. Although severe ADR incidence
was lower, the cost of treatment for severe ADRs was rela-
tively high. Therefore, we should focus on the prevention
of severe ADRs through ADR monitoring programmes.
Further, for ADRs that automatically improve after drug
withdrawal, the cost is relatively low, suggesting that stop-
ping the medicine altogether is the best treatment for
these kinds of ADRs.Competing interests
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